Johnson & Johnson (NYSE:JNJ) is Van Strum & Towne Inc.’s 9th Largest Position

Van Strum & Towne Inc. boosted its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 1.2% in the third quarter, Holdings Channel.com reports. The institutional investor owned 47,367 shares of the company’s stock after acquiring an additional 550 shares during the period. Johnson & Johnson makes up 3.1% of Van Strum & Towne Inc.’s portfolio, making the stock its 9th largest holding. Van Strum & Towne Inc.’s holdings in Johnson & Johnson were worth $7,377,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Hibernia Wealth Partners LLC bought a new stake in Johnson & Johnson during the third quarter valued at approximately $27,000. FNY Investment Advisers LLC bought a new position in Johnson & Johnson in the 3rd quarter worth $37,000. Tower View Wealth Management LLC grew its holdings in Johnson & Johnson by 183.3% during the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 165 shares during the period. Creative Capital Management Investments LLC increased its position in Johnson & Johnson by 43.0% in the third quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock worth $45,000 after buying an additional 86 shares in the last quarter. Finally, VitalStone Financial LLC bought a new position in shares of Johnson & Johnson in the second quarter worth about $48,000. Institutional investors own 68.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. UBS Group upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Wells Fargo & Company downgraded shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. TheStreet cut Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Eight research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $176.14.

Check Out Our Latest Stock Report on Johnson & Johnson

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.20% of the stock is owned by insiders.

Johnson & Johnson Price Performance

JNJ stock opened at $157.87 on Tuesday. Johnson & Johnson has a 52 week low of $144.95 and a 52 week high of $175.97. The firm has a market capitalization of $380.04 billion, a P/E ratio of 11.43, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a fifty day simple moving average of $158.18 and a two-hundred day simple moving average of $158.62. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same quarter last year, the business posted $2.35 earnings per share. The firm’s revenue was down 9.7% on a year-over-year basis. Analysts anticipate that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 34.47%.

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.